Skip to main content
Smart Investors Daily
IDEXX Laboratories, Inc. logo

NYSE · IDXX

IDEXX Laboratories, Inc.

Healthcare · Medical - Diagnostics & Research

$698.47

Down-$8.82 (-1.26%)

Updated Nov 20, 2026, 1:51 AM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
56.52B
P/E ratio
55.18
Dividend yield
0.00%
52-week range
$500.61 – $719.95
Volume
373.71K
Avg. volume
600.64K

Price performance · IDXX

IDXX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

IDXX closed at $698.47 after 20 trading sessions, up 23.24% for the selected period.

Last close
$698.47
Period change
+23.24%
Period low
$551.21
Period high
$706.65
Daily close
View OHLC price history
IDXX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$684.64$704.85$683.72$698.47373.71K
Nov 17, 2026$701.14$706.76$687.715$690.24400.85K
Nov 16, 2026$705.00$713.105$698.68$700.65491.06K
Nov 13, 2026$710.24$711.2289$702.53$704.23392.45K
Nov 12, 2026$711.68$712.88$696.715$698.02487.64K
Nov 11, 2026$688.04$703.84$680.00$702.59423.32K
Nov 10, 2026$700.00$700.00$682.58$696.64463.97K
Nov 9, 2026$682.35$709.26$680.89$706.65703.73K
Nov 6, 2026$652.12$680.57$650.00$676.04589.07K
Nov 5, 2026$702.00$704.03$664.81$670.71873.28K
Nov 4, 2026$686.23$713.74$681.70$698.551.4M
Nov 3, 2026$662.26$681.495$655.515$672.041.19M
Nov 2, 2026$625.00$673.19$620.20$671.641.98M
Oct 30, 2026$583.75$586.00$540.61$551.211.17M
Oct 29, 2026$570.17$576.17$568.01$575.98479.54K
Oct 28, 2026$556.78$567.77$555.2084$562.91351.84K
Oct 27, 2026$563.23$567.545$559.0301$561.25488.99K
Oct 26, 2026$564.23$571.75$557.94$570.21528.16K
Oct 23, 2026$564.80$569.555$558.29$560.38398.28K
Oct 22, 2026$562.01$568.67$558.39$566.76430.12K

Latest IDXX news

The latest Smart Investors Daily articles mentioning IDXX.

IDXX research

Overview

Company profile and research snapshot.

Company profile

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$803.57
Implied upside
—
Analysts
9
IDXX recent ratings
DateFirmRatingTarget
Nov 3, 2026UBSNeutral—
Nov 3, 2026Morgan StanleyOverweight—
Oct 27, 2026UBSNeutral—
Oct 16, 2026JP MorganOverweight—
Oct 12, 2026KeybancSector Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Nov 6, 2026

Board Member At IDEXX Laboratories Sells $844K Of Stock

A substantial insider sell was reported on November 5, by Daniel M Junius, Board Member at IDEXX Laboratories (NASDAQ:IDXX), based on the recent SEC filing. What Happened: Junius's recent move involves selling 1,200

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.